Kusajili – Clinical trials directory

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).

• Country Belgium, France, Germany, Italy, Korea, Republic of, Spain, Turkey, United States,
• organs None
• Specialty None

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia The purpose of this study is to determine the safety and effectiveness of different dose regimen of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.

• Country Canada, France, Germany, Italy, Spain, Sweden, United Kingdom, United States,
• organs None
• Specialty None

Barostim Neo System in the Treatment of Heart Failure The purpose of this clinical investigation is to evaluate the efficacy and safety of the CVRx Barostim Neo System in the treatment of patients with heart failure.

• Country Canada, France, Germany, Italy,
• organs None
• Specialty None

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma The purpose of this study is to assess the safety and pharmacokinetics, and determine the pediatric maximum tolerated dose and/or or recommended phase 2 dose of brentuximab vedotin.

• Country France, Germany, Italy, Mexico, Netherlands, Spain, United Kingdom, United States,
• organs None
• Specialty None

Faslodex in McCune Albright Syndrome The purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of a study drug called Faslodex (fulvestrant) in the treatment of progressive precocious puberty (early puberty) in girls with McCune-Albright syndrome (MAS).

• Country France, Germany, Italy, Russian Federation, United Kingdom, United States,
• organs None
• Specialty None

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q The purpose of this study is to investigate whether lenalidomide would reduce the number of red blood cell transfusions (RBC) needed in anemic (RBC transfusion-dependent) participants with low or intermediate-1 risk MDS without a deletion 5q chromosome abnormality. The study also investigated the safety of lenalidomide use in these participants. Two-thirds of the participants received oral lenalidomide and one-third of the participants received oral placebo.

• Country Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Israel, Italy, Japan, Poland, Portugal, Spain, Turkey, United Kingdom, United States,
• organs None
• Specialty None

Evaluation of the safety and efficacy of the Optimizer™ II and III systems with active fixation leads in subjects with heart failure resulting from systolic dysfunction Not provided at time of registration

• Country Czech Republic, France, Germany, Italy, Netherlands,
• organs None
• Specialty None

Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia The purpose of this clinical research study was to establish a recommended phase 2 once daily (QD) dose of dasatinib and to assess the efficacy of the investigational drug for relapsed or refractory (resistant to previous treatment) leukemia in children and adolescents. The side effects that this oral investigational drug may have in children, and the levels of the drug in the blood, will be studied at different doses.

• Country Austria, France, Germany, Italy, Netherlands, United Kingdom,
• organs None
• Specialty None

Kuvan® Adult Maternal Pediatric European Registry

• Country Austria, France, Germany, Italy, Netherlands, Slovakia, Spain, Sweden,
• organs None
• Specialty None

Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis The purpose of the study is to evaluate the clinical efficacy, safety and tolerability of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in subjects with active Ulcerative Colitis (UC).

• Country Australia, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Netherlands, New Zealand, Poland, Russian Federation, Ukraine, United States,
• organs None
• Specialty None